M
Mario Mesiti
Researcher at University of Messina
Publications - 52
Citations - 916
Mario Mesiti is an academic researcher from University of Messina. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 16, co-authored 52 publications receiving 896 citations.
Papers
More filters
Journal ArticleDOI
Cyclophosphamide, Methotrexate, and Fluorouracil Versus Tamoxifen Plus Ovarian Suppression as Adjuvant Treatment of Estrogen Receptor–Positive Pre-/Perimenopausal Breast Cancer Patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized Trial
Francesco Boccardo,Alessandra Rubagotti,Domenico Amoroso,Mario Mesiti,D. Romeo,P. Sismondi,Maurizia Giai,F. Genta,Paolo Pacini,V. Distante,A. Bolognesi,D. Aldrighetti,Antonio Farris +12 more
TL;DR: The combination of tamoxifen with ovarian suppression seems to be safe and to yield comparable results relative to standard CMF, and few patients who developed benign gynecologic changes in either group.
Journal ArticleDOI
Switching to anastrozole (ANA) vs continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian tamoxifen anastrozole (ITA) trial
Francesco Boccardo,Alessandra Rubagotti,Matteo Puntoni,Pamela Guglielmini,M. Porpiglia,Mario Mesiti,Michela Rinaldini,G. Paladini,V. Distante,R. Franchi +9 more
TL;DR: An additional analysis at a median follow-up time of 52 mos shows that switching to ANA after 2–3 years of TAM is well tolerated and significantly improves event-free (EFS) and progression-free survival (PFS) of postmenopausal ebc.
Journal ArticleDOI
Sequential Tamoxifen and Aminoglutethimide Versus Tamoxifen Alone in the Adjuvant Treatment of Postmenopausal Breast Cancer Patients: Results of an Italian Cooperative Study
Francesco Boccardo,Alessandra Rubagotti,Domenico Amoroso,Mario Mesiti,D. Romeo,C. Caroti,Antonio Farris,Giorgio Cruciani,Eugenio Villa,G. Schieppati,Giorgio Mustacchi +10 more
TL;DR: Switching patients from tamoxifen to aminoglutethimide treatment resulted in comparable event-free survival, but longer overall survival was achieved in patients who were switched to am inoglutEthimide as compared with those who continued to receive tamoxIFen.
Journal ArticleDOI
Quantitative study of blood-brain barrier permeability changes after experimental whole-brain radiation.
Domenico D'Avella,Rocco Cicciarello,Francesca Albiero,Mario Mesiti,Maria Ester Gagliardi,Elvio G. Russi,Antonio D'Aquino,Francesco Tomasello,Saverio d'Aquino +8 more
TL;DR: This work investigated the possibility of a change in blood-brain barrier function as a causative factor for early delayed whole-brain radiation-induced cerebral haemorrhage in rats.
Journal ArticleDOI
Unusual relapse of hepatocellular carcinoma.
Elvio G. Russi,Stefano Pergolizzi,Mario Mesiti,Massimo Rizzo,Antonio D'Aquino,Giuseppe Altavilla,V. Adarno +6 more
TL;DR: The risk of neoplastic seeding through biopsy and improved safety in surgical techniques justify the omission of diagnostic biopsy in patients who have surgical procedures.